Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 17, 2025

NORWEGIAN CRUISE LINE® UNVEILS SUN-SOAKED WINTER 2027/28 DEPLOYMENT AND BRINGS BACK FREE AT SEA PLUS™ BY POPULAR DEMAND DELIVERING PREMIUM OFFERINGS

View original at finance.yahoo.com
NORWEGIAN CRUISE LINE® UNVEILS SUN-SOAKED WINTER 2027/28 DEPLOYMENT AND BRINGS BACK FREE AT SEA PLUS™ BY POPULAR DEMAND DELIVERING PREMIUM OFFERINGS - New Season of Sailings Features Over 370 Voyages Across Nearly 50 Countries, Including Two Prima Class Ships in San Juan, Expanded Caribbean Adventures as well as Once-i…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With longer port stays, overnight calls, and our award-winning onboard experiences, guests can explore at their own pace and personalize every moment at ease

    80% confidence

  • We're thrilled to unveil our new immersive winter season, giving travelers the ultimate freedom to create their own adventure

    80% confidence

  • With the return of Free at Sea Plus, guests will enjoy even greater value and convenience, making it easier than ever to relax and focus on what truly matters – reconnecting with those who matter most

    80% confidence

  • Many of our Bahamas and Caribbean itineraries will visit our exclusive private island destination, Great Stirrup Cay, which will feature a new pier, an oversized heated pool, and the Great Tides Waterpark

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com